ArticleArchives of microbiology2026
Lactilactobacillus curvatus TH19-7: a broad-spectrum antimicrobial probiotic targeting skin pathogens and mitigating infection-associated dermal damage in vitro.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Silico and In Vitro Evaluation of Atriplex halimus: Antibacterial Activity, Molecular Docking, ADMET Profiling, and Cytotoxicity Assessment.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective management of skin infections requires antimicrobial agents that can eradicate pathogens and mitigate associated tissue damage. This in vitro study evaluates the potential of Lactilactobacillus curvatus TH19-7, isolated from kimchi, as a safe and broad-spectrum antimicrobial probiotic. The selected lactic acid bacterium was identified by 16S rRNA sequencing and biochemical profiling, followed by in vitro evaluation of antimicrobial activity (MIC/MBC), cellular morphology (SEM), safety (antibiotic susceptibility, hemolysis, bile salt hydrolase activity, and D-lactic acid production), antioxidant capacity (DPPH and ABTS assays), and anti-inflammatory effects assessed by macrophage viability and NO inhibition. The strain demonstrated significant bactericidal activity, with its cell-free supernatant inhibiting the growth of key cutaneous pathogens, including Staphylococcus aureus, Staphylococcus epidermis, Cutibacterium acnes, Pseudomonas aeruginosa, Escherichia coli (E. coli), and Candida albicans by 64.7-83.5% at 2.5 mg/mL. Minimum Inhibitory and Bactericidal Concentrations (MIC/MBC) confirmed high potency, with low MICs of 1.25 mg/mL against several targets. Crucially, scanning electron microscopy revealed that the antimicrobial mechanism involves direct cellular lysis and severe membrane deformation in bacterial cells, particularly with E. coli, with complete cell disruption. Beyond pathogen eradication, the strain exhibited significant radical scavenging capacity (ABTS IC₅₀ = 39.1 µg/mL) and suppressed nitric oxide production in macrophages by 34.8%, indicating potential to mitigate oxidative and inflammatory tissue damage. Furthermore, L. curvatus TH19-7 displayed a strong safety profile, demonstrating a non-hemolytic (γ-hemolytic) phenotype, susceptibility to a broad range of clinically relevant antibiotics, minimal D-lactate production, and demonstrated tolerance to simulated gastrointestinal stress conditions. These findings position L. curvatus TH19-7 as a promising topical probiotic that directly eliminates pathogens through membrane disruption and concurrently aid tissue recovery through immunomodulatory and antioxidant activities.
Indexed as
Identifiers
41724834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.